A niche biofilm science leader is scaling into an integrated, accredited lab platform—pairing surging CRO/analytical demand with high-margin IP optionality.
Overview
Innovotech Inc. (IOT.V) is a Canadian micro-cap biotechnology-enabled contract research and laboratory services company specializing in the science and eradication of microbial biofilms—highly treatment-resistant bacterial/fungal communities implicated in an estimated ~80% of infections and up to 1,000x more antibiotic resistant than planktonic organisms. Based in Edmonton and operating ISO 17025 and GMP-accredited capabilities, Innovotech sits at the intersection of medical device validation, pharmaceutical testing, and antimicrobial chemistry. The company’s model combines (1) high-margin contract research services for biofilm efficacy and device qualification (the primary growth engine, largely U.S.-driven), (2) recurring global product revenue from the MBEC Assay® kits and consumables (a widely used biofilm research tool that supports visibility and repeat purchasing), and (3) longer-dated IP optionality from proprietary antimicrobial silver compounds (InnovoSIL™) and a 60% interest in Nou Life Sciences (linked-molecule antioxidant delivery technology). In 2025 the firm hit an inflection point: Q3-25 delivered record revenue of $1.27M, exceeding the entirety of FY2023 revenue, signaling a transition from a boutique research shop to a scalable, integrated laboratory platform—reinforced by Keystone Labs integration and a 2026 amalgamation to streamline operations.